<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067118</url>
  </required_header>
  <id_info>
    <org_study_id>SU-01292010-4823</org_study_id>
    <secondary_id>17579</secondary_id>
    <nct_id>NCT01067118</nct_id>
  </id_info>
  <brief_title>A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.</brief_title>
  <official_title>Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Glycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to
      Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a
      breakfast meal.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was suspended due to lack of study drug
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for this first phase is the 3 hour area under the curve from baseline following a standardized breakfast meal.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary endpoint for this second phase is the 3 hour area under the curve from baseline following a standardized breakfast meal in the outpatient setting.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary endpoint for this third phase is daytime (6 am to midnight) average glucose values.is percent of CGMS glucose values in range (70-180 mg/dL) for the third week fo sensor data in each group.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Humalog U-100 Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LINjeta U-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LINjeta U-100 Insulin</intervention_name>
    <description>LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors</description>
    <arm_group_label>LINjeta U-100</arm_group_label>
    <other_name>VIAject U-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog U-100</intervention_name>
    <description>Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors</description>
    <arm_group_label>Humalog U-100 Insulin</arm_group_label>
    <other_name>Lispro U-100 insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1)Type 1 diabetes for at least 1 year

          1. The diagnosis of type 1 diabetes is based on the investigator¡-s judgment; C peptide
             level and antibody determinations are not needed.

             2) Age : 18 years old ¨C 49.99 years old 3) Continuous subcutaneous insulin infusion
             (CSII) therapy for at least 3 months 4) Participant consent demonstrated by signing
             IRB approved documents 6) HgA1c ¡Ü 9% 7) If participant is female with reproductive
             potential, willing to avoid pregnancy and pregnancy test negative.

             Exclusion Criteria:1) Chronic oral steroid use

             2) The presence of a significant medical disorder that in the judgment of the
             investigator will affect the wearing of sensors or the completion of any aspect of the
             protocol.

             3) Known clinical history of celiac disease or inflammatory bowel disease. 4)
             Participants will have a negative anti-endomysial antibody or anti-tissue
             transglutaminase antibody within one year of enrollment.

             5) Cystic Fibrosis 6) Inpatient psychiatric treatment in the past 6 months. 7)
             Currently pregnant or lactating, or anticipate getting pregnant in the next one year.

             8) Clinical diagnosis of gastroparesis. 9) Insulin binding capacity greater than 10
             microunits per litter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A. Buckingham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver School of Medicine Barbara Davis Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Bruce A. Buckingham</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

